Agendia, Inc., a global leader in personalized medicine and molecular cancer diagnostics, announces the value of its upcoming MammaPrint®70-Breast Cancer Recurrence Risk Test and BluePrint® Breast Cancer Molecular Subtype Test at the upcoming 2017 San Ant